Wells Fargo’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-4,391
| Closed | -$2.59K | – | 7331 |
|
|
2024
Q4 | $2.59K | Hold |
4,391
| – | – | ﹤0.01% | 6156 |
|
|
2024
Q3 | $3.46K | Hold |
4,391
| – | – | ﹤0.01% | 5984 |
|
|
2024
Q2 | $5.58K | Sell |
4,391
-174
| -4% | -$230 | ﹤0.01% | 5864 |
|
|
2024
Q1 | $6.34K | Buy |
4,565
+2,179
| +91% | +$3.6K | ﹤0.01% | 5848 |
|
|
2023
Q4 | $3.79K | Buy |
2,386
+34
| +1% | +$43 | ﹤0.01% | 5997 |
|
|
2023
Q3 | $3.34K | Buy |
2,352
+4
| +0.2% | +$6 | ﹤0.01% | 6017 |
|
|
2023
Q2 | $3.73K | Buy |
2,348
+37
| +2% | +$47 | ﹤0.01% | 6118 |
|
|
2023
Q1 | $1.94K | Buy |
2,311
+10
| +0.4% | +$14 | ﹤0.01% | 6228 |
|
|
2022
Q4 | $3.27K | Buy |
2,301
+250
| +12% | +$413 | ﹤0.01% | 5887 |
|
|
2022
Q3 | $4K | Hold |
2,051
| – | – | ﹤0.01% | 6000 |
|
|
2022
Q2 | $4K | Buy |
2,051
+4
| +0.2% | +$10 | ﹤0.01% | 6126 |
|
|
2022
Q1 | $6K | Buy |
2,047
+2,011
| +5,586% | +$7.03K | ﹤0.01% | 6436 |
|
|
2021
Q4 | $0 | Buy |
36
+1
| +3% | +$6 | ﹤0.01% | 7958 |
|
|
2021
Q3 | $0 | Sell |
35
-1
| -3% | -$8 | ﹤0.01% | 7658 |
|
|
2021
Q2 | $0 | Buy |
36
+12
| +50% | +$100 | ﹤0.01% | 7589 |
|
|
2021
Q1 | $0 | Buy |
+24
| New | +$200 | ﹤0.01% | 7514 |
|
Wells Fargo's CYTH Position: Q1 2025 in Review
Wells Fargo sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 4,391 shares — an estimated $2.59K sold.
Wells Fargo first reported a position in CYTH in Q1 2021 and held it in 16 quarters. The position peaked at $6.34K in Q1 2024. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.
- Wells Fargo reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Wells Fargo sold 4,391 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $2.59K.
- Wells Fargo first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2021 and held it in 16 quarters.
- Wells Fargo's Cyclo Therapeutics, Inc. Common Stock position peaked at $6.34K in Q1 2024.
- 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Wells Fargo's 13F filing for Q1 2025, filed 13 May 2025.